08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Amatuximab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg IV amatuximab once weekly with IV pemetrexed and IV cisplatin given on day 1 of each 3-week cycle...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

Amatuximab regulatory update

The European Commission granted Orphan Drug designation for Eisai's amatuximab to treat malignant pleural mesothelioma (MPM). The IgG1 antibody against glycoprotein-9 ( GP-9 ; CD42a ) is in Phase II testing for MPM and also...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

Amatuximab regulatory update

FDA granted Orphan Drug designation for amatuximab from Eisai's Morphotek Inc. subsidiary to treat malignant pleural mesothelioma (MPM). In May, interim data from the Phase II MORAb-009-003 trial in 89 chemotherapy-naïve patients with unresectable epithelial...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Amatuximab: Interim Phase II data

Interim data from the open-label, international Phase II MORAb-009-003 trial in 89 chemotherapy-naïve patients with unresectable epithelial or biphasic pleural MM showed that 5 mg/kg amatuximab on days 1 and 8 of a 21-day cycle...
08:00 , Dec 21, 2009 |  BioCentury  |  Strategy

Eisai Inspired to Morph

With more than a decade gone by without a homegrown NME reaching the market, Eisai Co. Ltd. decided early in 2008 that it needed to make some drastic changes. Inspired by its recently acquired Morphotek...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

MORAb-009: Phase II started

Eisai's Morphotek Inc. subsidiary began a single-arm, open-label, international Phase II trial (MORAb-009-003) to evaluate IV MORAb-009 given on days 1 and 8 of a 21-day cycle for 6 cycles plus pemetrexed and cisplatin in...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Clinical News

MORAb-009 regulatory update

The EC granted Orphan Drug designation to Eisai's MORAb-009 to treat pancreatic cancer. The IgG1 antibody against glycoprotein-9 ( GP-9 ) is in Phase II testing in patients with inoperable pancreatic cancer. Eisai acquired MORAb-009...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Clinical News

MORAb-009: Phase II started

Eisai's Morphotek Inc. subsidiary began a double-blind, international Phase II trial to evaluate gemcitabine plus MORAb-009 or placebo in up to 152 patients. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan   Product: MORAb-009   Business:...
07:00 , Mar 26, 2007 |  BioCentury  |  Strategy

Building a cancer pipeline

Building a cancer pipeline...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

Morphotek, Eisai deal

Eisai bolstered its oncology portfolio last September by acquiring the cancer product line of Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.) (see BioCentury, Sept. 11, 2006). Eisai also has E7389 , a synthetic analog of...